TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Articolo
Data di Pubblicazione:
2013
Citazione:
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial / Fuchs, C.s., Fakih, M., Schwartzberg, L., Cohn, A.l., Yee, L., Dreisbach, L., Kozloff, M.f., Hei, Y.j., Galimi, F., Pan, Y., Haddad, V., Hsu, C.p., Sabin, A., Saltz, L.. - In: CANCER. - ISSN 1097-0142. - (2013). [10.1002/cncr.28353]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Fuchs, Cs; Fakih, M; Schwartzberg, L; Cohn, Al; Yee, L; Dreisbach, L; Kozloff, Mf; Hei, Yj; Galimi, Francesco; Pan, Y; Haddad, V; Hsu, Cp; Sabin, A; Saltz, L.
Link alla scheda completa:
Pubblicato in: